Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study (Q38375967)
Jump to navigation
Jump to search
scientific article published on March 2010
Language | Label | Description | Also known as |
---|---|---|---|
English | Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study |
scientific article published on March 2010 |
Statements
1 reference
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study (English)
1 reference
Giovanni Martinelli
1 reference
Herve Dombret
1 reference
Gerhard Ehninger
1 reference
Richard A Larson
1 reference
Michael B Lilly
1 reference
Oliver G Ottmann
1 reference
Neil P Shah
1 reference
Josy J Reiffers
1 reference
Martin C MĂĽller
1 reference
Aude Charbonnier
1 reference
Eduardo Bullorsky
1 reference
Mary Brigid Bradley-Garelik
1 reference
Chao Zhu
1 reference
1 March 2010
1 reference
1 reference
85
1 reference
3
1 reference
164-170
1 reference
Identifiers
1 reference
1 reference